Evaluation of Pirfenidone as a New Postoperative Antiscarring Agent in Experimental Glaucoma Surgery

Abstract

Postoperative use of 0.5% pirfenidone eye drops was associated with improved trabeculectomy bleb survival in a rabbit model. Pirfenidone eye drops may be a safe and effective antiscarring agent in glaucoma filtration surgery.

The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on

“…116 Topical application has been studied in human scleroderma 117 and in glaucoma scarring models. 118 Finally, the topical use of anti-inflammatory monoclonal antibodies, such as the anti TNFα drugs that could be given subconjunctivally, should be evaluated.…”

Antifibrotic effects of pirfenidone on Tenon’s fibroblasts in glaucomatous eyes: comparison with mitomycin C and 5-fluorouracil

“…Excessive subconjunctival scarring in the sclerostomy site or in bleb connective tissue are a result of proliferation and aberrant extracellular matrix (ECM) production during wound healing [25]. TGF-ß is the primary inducer of fibrosis, and is known to induce the expression of additional fibrogenic mediators, facilitate myofibroblast differentiation, and induce epithelial-mesenchymal transition [29].…”

“…PFD also showed antifibrotic effects in human pterygium fibroblasts [24]. Additionally, postoperative administration of 0.5 % PFD eyedrops demonstrated a similar antifibrotic effect to that of perioperative MMC in a rabbit model of experimental GFS [25]. However, the effects of PFD in human glaucomatous eyes have not yet been reported.…”

Topical Silver Nanoparticles Result in Improved Bleb Function by Increasing Filtration and Reducing Fibrosis in a Rabbit Model of Filtration Surgery

“…Many have been tried in both animals and humans with variable degrees of success. [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] Elemental silver has long been used as a medical agent for its anti-infective properties, and has been used in ophthalmology in silver nitrate form as an agent to prevent ophthalmia neonatorum. More recently, silver nanoparticles (AgNPs, diameter < 100 nm) that retain broad spectrum antibacterial activity have been developed.…”